In8bio, Inc. (INAB) · Nov 5, 2026 · Earnings

IN8bio earnings beat, but cash falls ahead of INB-619 data

Beat — EPS loss $0.24 vs ~$0.34 consensus

IN8bio’s third-quarter earnings beat published estimates, while higher R&D spending and falling cash keep financing risk central ahead of INB-619 data.

IN8bio is a clinical-stage biotech shifting emphasis toward its γδ T-cell engager platform, especially preclinical candidate INB-619, while still advancing INB-100 and the INB-200/400 glioblastoma programs. Its prior plan already called for initial INB-619 animal data in the second half of 2026 and identified additional capital as important to funding the pipeline.

The quarter beat the narrow financial bar, but this is an expense-and-cash story rather than a clinical inflection point. The reported $0.24 per-share loss was better than published estimates of roughly $0.34, helped partly by the much larger share base versus last year. R&D spending rose as the company paid for T-cell-engager preclinical work, while G&A also increased. The filing says, “The increase was due primarily to preclinical costs associated with the Company’s T cell engager platform.” 〔0〕

Q3 2026Q3 2025Consensus
R&D expense (Financial Highlights)$2.6M (+23.5%)$2.1M
G&A expense (Financial Highlights)$2.1M (+13.9%)$1.9M
Net loss (Financial Highlights)$4.6M (+19.1%)$3.9M
Loss per share (Financial Highlights)$0.24$0.85~$0.34
Cash (Balance Sheets)$14.0M$10.7M

Execution is moving toward the next data point, but the filing does not deliver new efficacy evidence. IN8bio added an experienced γδ T-cell-engager R&D leader, cited external recognition of INB-619, and reiterated that initial in vivo data remain on track by year-end. Those are supportive validation and execution signals, but the key proof point is still ahead; the filing reports no new animal results, clinical readout, or regulatory pathway. The company says it “remain[s] on track to report initial in vivo preclinical data for INB-619 by year-end 2026.” 〔1〕

The balance sheet is the main constraint on the otherwise modestly positive quarter. Cash fell to $14.0 million from $27.1 million at December 31, 2025, while the accumulated deficit widened to $155.6 million. Prior disclosures already warned that existing resources were not expected to fund the business beyond April 2027 and that additional financing or strategic arrangements would be needed. The current filing does not announce new financing, so the company is advancing the platform while leaving the funding question unresolved.

Bottom line: IN8bio modestly cleared the earnings bar and maintained its key INB-619 timetable, but the business story barely changes: the important scientific evidence is still ahead, and cash remains the limiting factor. $

Bottom line: The quarter is slightly better than expected on EPS, but it does not yet materially de-risk IN8bio’s platform or financing path.

What to watch next

Initial INB-619 in vivo data, by year-end 2026

Original filing on SEC EDGAR

IN8bio earnings beat, but cash falls ahead of INB-619 data | INAB Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.